Report of FDA Gorlin Syndrome Patient-Led Listening Session 11/09/2020
Session Objectives: Educate the FDA staff on the complex issues of Gorlin syndrome (GS), both related to the basal cell carcinoma’s (BCCs) and the variety of physical manifestations
Virtual Patient Conference October 24 @ 11am Eastern
We are proud to announce our first virtual conference, “Forging New Paths to Find a Cure,” taking place on Saturday, October 24, 2020 from 11:00 am to 5:15 pm EST. Click here to
GSA Town Hall, Sunday September 13 @ 8PM Eastern
Julie Breneiser, Executive Director Notes Hi Everyone and thanks so much for making the time to join this town hall. A couple of pieces of housekeeping before I start. Please be sure
Palvella Therapeutics Completes $45 Million Series C Financing
The Gorlin Syndrome Alliance has been working with Palvella Therapeutics since 2017. We look forward to continuing our collaboration to move the clinical trial of PTX-367 (QTORIN™
Sunscreen Tips & Tricks
The Gorlin Syndrome Alliance asked Dr. Jean Tang, Professor of Dermatology at Stanford University, some frequently asked questions about sunscreen. What is the difference between
Rare Cancer Coalition Webinar: Building Relationships Between Patient Advocacy Groups and Pharma
On Tuesday, April 28, Julie Breneiser, the Executive Director of the Gorlin Syndrome Alliance will be a presenter in a NORD webinar with Camilla Krogh Lauritzen, Chief Patient Officer
Regional Conference in Minneapolis to be Postponed
Due to the global COVID-19 pandemic, the Gorlin Syndrome Alliance has decided to postpone the One-Day Member Meeting scheduled for June 6, 2020 in Minneapolis, Minnesota. As soon as a
BASAL CELL NEVUS SYNDROME; BCNS
A number sign (#) is used with this entry because basal cell nevus syndrome (BCNS) can be caused by mutations in the PTCH1 gene (601309) on chromosome 9q22, the
Topical 5-Fluorouracil is a Novel Targeted Therapy for the Keratocystic Odontogenic Tumor.
Purpose: The antimetabolite drug, 5-fluorouracil (5-FU), is used in the treatment of various cancers, including basal cell carcinomas (BCCs). The authors hypothesized that
Nevoid Basal Cell Carcinoma Syndrome.
Clinical characteristics. Nevoid basal cell carcinoma syndrome (NBCCS) is characterized by the development of multiple jaw keratocysts, frequently beginning in the second decade of